NCT00373659View on ClinicalTrials.gov

An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Ranibizumab (Lucentis)

Trial Locations (1)

33136

Bascom Palmer Eye Instiyute, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT00373659 - An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD | Biotech Hunter | Biotech Hunter